Induction of melanoma antigen-specific cytotoxic T lymphocytes in vitro by stimulation with B7-expressing human melanoma cell lines

Journal of Immunotherapy

Volumn 21, Issue 2, 1998, Pages 95-108

  Fenton, Robert G ^a   Turcovski Corrales, Susan M ^b   Taub, Dennis D ^b,c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

^c NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

B7; Costimulation; Immunotherapy; T lymphocytes; Tumor

Indexed keywords

ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CROSS LINKING; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MELANOMA; MIXED LYMPHOCYTE CULTURE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

EID: 0031890475     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-199803000-00002     Document Type: Article

References (57)

1. Rosenberg SA, Packard BS, Aebersold PM, et al. Use of tumorinfiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med 1988;319:1676-80.
2. Van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991;254:1643-7.
3. Boel P, Wildmann C, Sensi ML, et al. BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity 1995;2:167-75.
4. Kawakami Y, Eliyahu S, Delgado CH, et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA 1994;91:3515-9.
5. Coulie PG, Brichard V, Van Pel A, et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1994;180:35-42.
6. Kawakami Y, Eliyahu S, Delgado CH, et al. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 1994;91:6458-62.
7. Bakker AB, Schreurs MW, de Boer AJ, et al. Melanocyte lineagespecific antigen gplOO is recognized by melanoma-derived tumorinfiltrating lymphocytes. J Exp Med 1994;179:1005-9.
8. Cox AL, Skipper J, Chen Y, et al. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 1994;264:716-9.
9. Wang RF, Robbins PF, Kawakami Y, Kang X-Q, Rosenberg SA. Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes. ] Exp Med 1995;181:799-804.
10. Brichard V, Van Pel A, Wolfel T, et al. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1993;178:489-95.
11. Kawakami Y, Eliyahu S, Sakaguchi K, et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med 1994;180:347-52.
12. Kawakami Y, Eliyahu S, Jennings C, et al. Recognition of multiple epitopes in the human melanoma antigen gplOO by tumorinfiltrating T lymphocytes associated with in vivo tumor regression. J Immunol 1995;154:3961-8.
13. Darrow TL, Singluff CL Jr, Seigler HF. The role of HLA class I antigens in recognition of melanoma cells by tumor-specific cytotoxic T lymphocytes. J Immunol 1989;142:3329-35.
14. Perkus ME, Tartaglia J, Paoletti E. Poxvirus-based vaccine candidates for cancer, AIDS, and other infectious diseases. J Leukocyte Biol 1995;58:1-13.
15. Zhai Y, Yang JC, Kawakami Y, et al. Antigen-specific tumor vaccines: development and characterization of recombinant adenoviruses encoding MARTI or gplOO for cancer therapy. J Immunol 1996;156:700-10.
16. + cytotoxic T lymphocyte responses. J Immunol 1992;148:2357-62.
17. Raychaudhuri S, Tonks M, Carbone F, Ryskamp T, Morrow WJ, Hanna N. Induction of antigen-specific class I-restricted cytotoxic T cells by soluble proteins in vivo. Proc Natl Acad Sci USA 1992;89:8308-12.
18. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor a. J Exp Med 1994;179:1109-18.
19. Mayordomo JI, Zorina T, Storkus WJ, et al. Bone marrow-derived dendritic cells pulsed with synthetic peptides elicit protective and therapeutic antitumor immunity. Nat Med 1995;1:1297-302.
20. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and longlasting anti-tumor immunity. Proc Natl Acad Sci USA 1993;90:3539-43.
21. Schwartz RH. Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 1992;71:1065-8.
22. Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 1991;174:61-9.
23. Linsley PS, Ledbetter JA. The role of the CD28 receptor during T-cell responses to antigen. Ann Rev Immunol 1993;11:191-212.
24. Guinan EC, Gribben JG, Boussiotis VA, Freeman GJ, Nadler LM. Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity. Blood 1994;84:3261-82.
25. June CH, Bluestone JA, Nadler LM, Thompson CB. The B7 and CD28 receptor families. Immunol Today 1994;15:321-30.
26. Mosman TR, Sad S. The expanding universe of T-cell subsets: Thl, Th2 and more. Immunol Today 1996;17:138-46.
27. Schwartz RH. A cell-culture model of T-lymphocyte clonal anergy. Science 1990;248:1349-56.
28. Harding FA, McArthur JG, Gross JA, Raulet DH, Allison JP. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 1992;356:607-9.
29. Gimmi CD, Freeman GJ, Gribben JG, Gray G, Nadler LM. Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. Proc Natl Acad Sci USA 1993;90:6586-90.
30. Inaba K, Witmer-Pack M, Inaba M, et al. The tissue distribution of the B7-2 costimulator in mice: abundant expression on dendritic cells in situ and during maturation in vitro. J Exp Med 1994;180:1849-60.
31. Hathcock KS, Laszlo G, Pucillo C, Linsley P, Hodes RJ. Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function. J Exp Med 1994;180:631-40.
32. Vandenberghe P, Delabie J, de Boer M, De Wolf-Peeters C, Ceuppens JL. In situ expression of B7/BB1 on antigen-presenting cells and activated B cells: an immunohistochemical study. Int Immunol 1993;5:317-21.
33. Thompson CB. Distinct roles for the costimulatory lignads B7-1 and B7-2 in T helper cell differentiation? Cell 1995;81:979-82.
34. Allison JP, Krummel MF. The yin and yang of T cell costimulation. Science 1995;270:932-3.
35. Jenkins MK. The ups and downs of T cell costimulation. Immunity 1994;1:443-6.
36. Walunas TL, Lenshow DJ, Bakkar CY, et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994;1:405-13.
37. Waterhouse P, Penninger JM, Timms E, et al. Lymphoproliferative disorders with early lethality in mice deficient in ctla-4. Science 1995;270:985-8.
38. Hellström KE, Hellström I, Chen L. Can co-stimulated tumor immunity be therapeutically efficacious? Immunol Rev 1995;145:123-45.
39. Chen L, Asha S, Brady WA, et al. Co-stimulation of anti-tumor immunity by the B7 counter-receptor for the lymphocyte molecules CD28 and CTLA-4. Cell 1992;71:1093-102.
40. + T cells by B7-transfected melanoma cells. Science 1993;259:368-70.
41. Baskar S, Ostrand-Rosenberg S, Nabavi N, Nadler LM, Freeman GJ, Glimcher LH. Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major-histocompatibility-complex-class II molecules. Proc Natl Acad Sci USA 1993;90:5687-90.
42. Chen L, McGowan P, Ashe S, Johnston J, Li Y, Hellström I, Hellström KE. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J Exp Med 1994;179:523-32.
43. Fenton RG, Sznol M, Luster DG, Taub DD, Longo DL. A phase I trial of B7-transfected or parental lethally irradiated allogeneic melanoma cell lines to induce cell-mediated immunity against tumor-associated antigen presented by HLA-A2 or HLA-A 1 in patients with stage IV melanoma. Hum Gene Ther 1995;6:87-106.
44. Turcovski-Corrales SM, Fenton RG, Peltz G, Taub DD. CD28:B7 interactions promote T cell adhesion. Eur J Immunol 1995;25:3087-93.
45. Thompson CB, Lindsten T, Ledbetter JA, et al. CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines. Proc Natl Acad Sci USA 1989;86:1333-7.
46. + cytotoxic T lymphocytes in the absence of exogenous help. J Exp Med 1993;177:1791-6.
47. Dohring C, Angman L, Spagnoli G, Lanzavecchia A. T-helper-and accessory-cell-dependent cytotoxic responses to human tumor cells transfected with a B7 retroviral vector. Int J Cancer 1994;57:754-9.
48. Ding M, Beck RJ, Keller CJ, Fenton RG. Cloning and analysis of MAGE-1-related genes. Biochem Biophys Res Commun 1994;202:549-55.
49. Iezzi G, Protti MP, Rugarli C, Bellone M. B7.1 expression on tumor cells circumvents the need of professional antigen presentation for in vitro propagation of cytotoxic T cell lines. Cancer Res 1996;56:11-5.
50. Sule-Suso J, Arienti F, Melani C, Colombo MP, Parmiani G. A B7-1-transfected human melanoma line stimulates proliferation and cytotoxicity of autologous and allogeneic lymphocytes. Eur J Immunol 1995;25:2737-42.
51. Dustin ML, Springer TA. Role of lymphocyte adhesion receptors in transient interactions and cell locomotion. Annu Rev Immunol 1991;9:27-66.
52. Dubey C, Croft M, Swain SL. Costimulation requirements of naive CD4+ T cells. J Immunol 1995;155:45-57.
53. Stevens EJ, Jackin L, Robbins PE, et al. Generation of tumorspecific CTLs from melanoma patients by using peripheral blood stimulated with allogeneic melanoma tumor cell lines. J Immunol 1995;154:762-71.
54. Townsend SE, Su FW, Atherton JM, Allison JP. Specificity and longevity of antitumor immune responses induced by B7transfected tumors. Cancer Res 1994;54:6477-83.
55. Ding L, Linsley PS, Huang L-Y, Germain RN, Shevach EM. IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression. J Immunol 1993;151:1224-34.
56. Alexandrow MG, Moses HL. Transforming growth factor β and cell cycle regulation. Cancer Res 1995;55:1452-7.
57. Mizoguchi H, O’Shea JJ, Longo DL, Loeffler CM, Me Vicar DW, Ochoa AC. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 1992;258:1795-8.